News

Published on 13 Sep 2022 on Benzinga via Yahoo Finance

FDA Clears Akouos' Gene Therapy Trial For Genetic Form Of Hearing Loss


Article preview image

The FDA has signed off Akouos Inc's (NASDAQ: AKUS) Investigational New Drug application to initiate a Phase 1/2 trial of AK-OTOF, gene therapy for otoferlin gene (OTOF)-mediated hearing loss.OTOF-mediated hearing loss is a form of sensorineural hearing loss caused by mutations in the otoferlin gene, which encodes otoferlin. This protein enables the inner hair cells of the cochlea to release neurotransmitter vesicles in response to stimulation by sound to activate auditory neurons.The Phase 1/2 trial is designed to evaluate the safety and tolerability of escalating doses of AK-OTOF administered unilaterally to trial participants with OTOF-mediated hearing loss.It will also assess efficacy through clinical measures such as ABR, an objective, clinically accepted endpoint.Nonclinical data demonstrated that AK-OTOF in Otof knockout mice results in durable expression of human otoferlin protein sufficient for sustained restoration of auditory function.In both mice and non-human primates, AK-OTOF was systemically and locally well tolerated, and no adverse effects were observed.The company plans to provide an update on clinical trial initiation activities later this year.Price Action: AKUS shares are down 5.14% at $3.32 on the last check Tuesday.

See more from Benzinga

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
10 Most Promising Gene Therapy Companies to Watch

In this piece, we will take a look at the ten most promising gene therapy companies to watch. For...

Insider Monkey via Yahoo Finance 14 Nov 2022

Eli Lilly Dividend: Does Eli Lilly Pay Dividends?

Yes, Eli Lilly and Company (NYSE: LLY) pays dividends but there is more to investing in this stoc...

Entrpreneur 27 Oct 2022

The Zacks Analyst Blog Highlights J&J, Roche, Eli Lilly and AbbVie

For Immediate Release Chicago, IL – October 24, 2022 – Zacks.com announces the list of stocks fea...

Zacks via Yahoo Finance 24 Oct 2022

Akouos (AKUS) Surges on $610M Buyout Deal With Eli Lilly

Shares of Akouos AKUS skyrocketed 88.16% after the company announced a buyout agreement for appro...

Zacks via Yahoo Finance 20 Oct 2022

Eli Lilly (LLY) to Buy Hearing Loss Gene Therapy Maker Akouos

Eli Lilly and Company LLY announced a definitive agreement to acquire Boston-based Akouos, AKUS, ...

Zacks via Yahoo Finance 19 Oct 2022

Why Akouos Stock Is on Fire Today

What happened Shares of small-cap gene therapy company Akouos (NASDAQ: AKUS) popped by as much as...

Motley Fool 18 Oct 2022

Why Akouos Shares Are Trading Sharply Higher? Here Are 36 Stocks Moving In Tuesday's Mid-Day Session...

Why Akouos Shares Are Trading Sharply Higher? Here Are 36 Stocks Moving In Tuesday's Mid-Day Sess...

Investing.com 18 Oct 2022

Eli Lilly to acquire Akouos for up to about $610 million and develop gene therapies for hearing loss

Eli Lilly and Co. said Tuesday it has entered an agreement to acquire Akouos Inc. a company devel...

MarketWatch 18 Oct 2022

Akouos, Inc. (AKUS) Upgraded to Strong Buy: Here's Why

Akouos, Inc. (AKUS) could be a solid choice for investors given its recent upgrade to a Zacks Ran...

Zacks via Yahoo Finance 10 Oct 2022

FDA Clears Akouos' Gene Therapy Trial For Genetic Form Of Hearing Loss

The FDA has signed off Akouos Inc's (NASDAQ: AKUS) Investigational New Drug application to initia...

Benzinga via Yahoo Finance 13 Sep 2022